Slide 1: AFT Pharmaceuticals Investor Presentation
AFT PHARMACEUTICALS Investor Presentation May 2016
Slide 2: Important Notice
IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New Zealand dollars (NZ$)
Slide 3: Presenting Today
PRESENTING TODAY . . . Dr Hartley Atkinson Founded AFT in 1997 along with his wife, Marree Previously Sales & Marketing Director, Medical Director, Founder and Chief Executive Officer Product Manager and Medical Manager at Swiss multinational pharmaceutical company, Roche Malcolm Tubby Involved with
Slide 4: FY2016 Highlights
FY2016 HIGHLIGHTS 98 countries that Maxigesic is licensed in 4 countries that Maxigesic is launched and sold in 12 number of clinical studies AFT will have running in FY2017 $65.8m total income for FY2016* $28.1m available cash as at 31 March 2016 Investor Presentation 3 * Total income comprises Ope
Slide 5: Maxigesic Update
MAXIGESIC UPDATE UK – launch pending soon Eastern Europe – launch pending soon Italy – successful launch and first royalty booked in May 2016 UAE – sales doubling in second year of sales Singapore – launch in June 2016 Australia – down scheduled to S2 – can be advertised – codeine rescheduling decis
Slide 6: Maxigesic Highlights
MAXIGESIC HIGHLIGHTS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries to 98 as at 31 March 2016. Clinical Trials for Maxigesic oral dose forms are well underway with studies running in Amman, Jordan; various cent
Slide 7: Financial Performance – Revenue Growth
FINANCIAL PERFORMANCE – REVENUE GROWTH Operating revenue, FY2000 – FY2016 70 60 Operating revenue (NZ$m) 10 year C AGR: 19% 50 40 30 20 10 - 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 FY2015 Operating revenue by region FY2016 Operating revenue by region Southeast Rest of Southeast R
Slide 8: Financial Performance – Revenue by Region and Channel
FINANCIAL PERFORMANCE – REVENUE BY REGION AND CHANNEL Operating revenue by region, FY2014 – FY2016 NZ$000's, year ended 31 March 2014 % of total 2015 % of total 2016 % of total Australia 20,035 40.9% 26,324 46.8% 31,224 48.8% YoY Growth - 31.4% 18.6% New Zealand 28,790 58.8% 29,398 52.3% 31,135 48.7
Slide 9: Financial Performance – Summary P&L
FINANCIAL PERFORMANCE – SUMMARY P&L NZ$000's, year ended 31 March 2016 % of revenue 2015 % of revenue Revenue 64,014 56,241 Cost of sales (40,435) 63.2% (35,083) 62.4% Gross profit 23,579 36.8% 21,158 37.6% Gross profit % Other income 2,295 3.6% 1,270 2.3% Selling and distribution expenses (19,634)
Slide 10: Financial Performance – Summary Balance Sheet
FINANCIAL PERFORMANCE – SUMMARY BALANCE SHEET NZ$000's, as at 31 March 2016 2015 ASSETS Current assets Inventories 17,686 14,686 Trade and other receivables 16,288 11,251 Cash and other equivalents 28,055 4,700 Current income tax asset 26 88 Total current assets 62,055 30,725 Non-current assets Prop
Slide 11: Financial Performance – Summary Cashflow Statement
FINANCIAL PERFORMANCE – SUMMARY CASHFLOW STATEMENT NZ$000's, year ended 31 March 2016 2015 Net cash (used in)/generated from operating activities (14,429) (13,105) Net cash (used in) investing activities (694) (483) Net cash generated from financing activities 36,705 17,135 Net increase in cash 21,5
Slide 12: Clinical Study Program
CLINICAL STUDY PROGRAM • 12 studies across the AFT portfolio • 1500+ patients • 7 countries - Australia, Jordan, Mexico, New Zealand, Russia, United Kingdom, United States • Clinical Trials for Maxigesic oral dose forms are well underway with studies running in Amman, Jordan; various centres in New
Slide 13: NasoSURF Nebuliser
NASOSURF NEBULISER DRUG DELIVERY AND TREATMENT SINUS CONDITIONS A handheld ultrasonic nasal mesh nebuliser for the The NasoSURF Nebuliser has desirable features Product over currently marketed nebulisers, which are not intranasal delivery of medication and treatment of description approved for deliv
Slide 14: NasoSURF versus German Gold Standard
NASOSURF VERSUS GERMAN GOLD STANDARD NasoSURF vs Pari Sinus IntraNasal Distribution 13
Slide 15: Summary of Near Term Plans
SUMMARY OF NEAR TERM PLANS Launch Maxigesic in new countries Advance Maxigesic registrations in North America Further licensing agreements Clinical studies of key innovative products NasoSURF clinical trials with pilot devices Achieve first registrations for NasoSURF as a Medical Device Build revenu